MSH2 and cancer: Collectively, these findings were consistent with the MSH2 c.2006G>T variant predisposing to tumorigenesis in both MSH2-deficient cancers, most definitively in the proband’s rectal cancer, whilst arguing against a role for EPCAM deletion and the MSH6 c.3936_4001+8dup variant in their development.